REGENERON PHARMACEUTICALS, INC. (REGN) Form 10-Q — Oct 30, 2026
Regeneron's Q3 2026 revenue rose 36% year-over-year to $5.12 billion with diluted EPS of $18.45 versus $13.62 a year ago, driven by Dupixent global sales of $6.54 billion (+35%) and its share of Sanofi collaboration profits. The quarter also reflects a mixed eye-care picture: EYLEA HD U.S. sales grew 63% globally to $2.85 billion while legacy EYLEA U.S. sales fell 41% on biosimilar competition, leaving combined EYLEA franchise sales down 15%.
Key figures
- Eps
- 18.45
- Total Debt
- 1987000000
- Revenue Yoy
- 36% (Q3 2026 vs Q3 2025: $5,115.8M vs $3,754.3M)
- Eps Prior Year
- 13.62
- Shares Outstanding
- 101,630,713 Common Stock + 1,817,146 Class A as of October 22, 2026
- Eylea us q3 sales
- 399700000
- Nine month revenue
- $13,011.9M vs $10,458.6M prior year
- Eylea hd us q3 sales
- 698800000
- Nine month net income
- $3,972.8M vs $3,660.3M
- Eylea us sales decline
- -41% YoY
- Nine month diluted eps
- 37.37
- Libtayo global q3 sales
- 550000000
- Sanofi amendment upfront
- $1.0 billion (recorded in Q4 2026)
- Sanofi amendment milestones
- up to $7.0 billion
- Quarterly dividend per share
- 0.94
- Revolving credit availability
- $750.0 million
- Sanofi collaboration revenue q3
- 2724000000
- Repurchase authorization remaining
- $2.157 billion
- Capital expenditure guidance fy2026
- $1.050 billion to $1.100 billion
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.